Autolus Therapeutics plc ADR [NASDAQ: AUTL] gained 1.43% or 0.04 points to close at $2.84 with a heavy trading volume of 3809600 shares.
The daily chart for AUTL points out that the company has recorded -26.61% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 1.30M shares, AUTL reached to a volume of 3809600 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Autolus Therapeutics plc ADR [AUTL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUTL shares is $10.76 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUTL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Autolus Therapeutics plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 18, 2024. The new note on the price target was released on November 15, 2024, representing the official price target for Autolus Therapeutics plc ADR stock. Previously, the target price had yet another raise to $10, while Deutsche Bank analysts kept a Buy rating on AUTL stock.
The Average True Range (ATR) for Autolus Therapeutics plc ADR is set at 0.30, with the Price to Sales ratio for AUTL stock in the period of the last 12 months amounting to 74.90. The Price to Book ratio for the last quarter was 1.58, with the Price to Cash per share for the same quarter was set at 2.47.
Trading performance analysis for AUTL stock
Autolus Therapeutics plc ADR [AUTL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.65. With this latest performance, AUTL shares dropped by -36.47% in over the last four-week period, additionally sinking by -26.61% over the last 6 months – not to mention a drop of -29.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUTL stock in for the last two-week period is set at 32.80, with the RSI for the last a single of trading hit 29.01, and the three-weeks RSI is set at 35.85 for Autolus Therapeutics plc ADR [AUTL]. The present Moving Average for the last 50 days of trading for this stock 3.81, while it was recorded at 2.93 for the last single week of trading, and 4.44 for the last 200 days.
Autolus Therapeutics plc ADR [AUTL]: A deeper dive into fundamental analysis
Autolus Therapeutics plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.64 and a Current Ratio set at 13.64.
Autolus Therapeutics plc ADR [AUTL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Autolus Therapeutics plc ADR posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.19. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AUTL.
An analysis of Institutional ownership at Autolus Therapeutics plc ADR [AUTL]
The top three institutional holders of AUTL stocks are: SYNCONA PORTFOLIO LTD with ownership of 21.35 million shares, which is approximately 9.6083%. BLACKSTONE INC., holding 20.49 million shares of the stock with an approximate value of $$71.29 million in AUTL stocks shares; and BLACKSTONE INC., currently with $$62.26 million in AUTL stock with ownership which is approximately 8.0523%.
